Smilax Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
- Paid Up Capital ₹ 1.40 Cr
- Company Age 33 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 M
- Revenue Growth %
- Profit Growth 113.37%
- Ebitda 14.06%
- Net Worth 0.03%
- Total Assets 0.03%
About Smilax Pharmaceuticals
Smilax Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 July 1991 and has a history of 33 years and seven months. Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.40 Cr.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mukut Goyal and Mukta Goyal serve as directors at the Company.
Company Details
-
Location
Jaipur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232RJ1991PTC006078
-
Company No.
006078
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Jul 1991
-
Date of AGM
02 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Smilax Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukut Goyal
|
Director | 08-Jul-1991 | Current |
|
Mukta Goyal
|
Director | 08-Jul-1991 | Current |
Financial Performance of Smilax Pharmaceuticals.
Smilax Pharmaceuticals Private Limited, for the financial year ended 2024, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 113.37% increase in profit. The company's net worth moved up by a moderate rise of 0.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Smilax Pharmaceuticals?
In 2024, Smilax Pharmaceuticals had a public holding of 35.71%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Biogenetic Drugs Private LimitedMukut Goyal is a mutual person
-
Smilax Psyllium Impex LlpMukut Goyal and Mukta Goyal are mutual person
-
Cynamid Pharmachem Llp
Mukut Goyal is a mutual person
-
Shiana Impex Llp
Mukut Goyal and Mukta Goyal are mutual person
-
Duramed Healthcare (India) Llp
Mukut Goyal and Mukta Goyal are mutual person
-
Wright Care Drugs Private Limited
Mukut Goyal and Mukta Goyal are mutual person
Charges (Loans)
₹0
₹0.50 Cr
Charges Breakdown by Lending Institutions
- Union Bank Of India : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Mar 2009 | Union Bank Of India | ₹5.00 M | Satisfied |
How Many Employees Work at Smilax Pharmaceuticals?
Unlock and access historical data on people associated with Smilax Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Smilax Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Smilax Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.